In further support, clinical studies have shown that MC4R mediates the development of hypertension in overweight adults, as individuals with a loss‐of‐function mutation to MC4R had lower blood pressure, reduced hypertension prevalence and lower urinary noradrenaline metabolites than BMI‐ and insulin resistance‐matched control participants (Greenfield et al., 2009). Here, MC4R is linked to hypertensive disorder.